

**Medtronic**

Engineering the extraordinary

# Medtronic plc

## Q1 FY25

Earnings presentation

August 20<sup>th</sup>, 2024



**Medtronic**

## Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the US Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this presentation, including to reflect future events or circumstances.

## Non-GAAP financial measures

Certain information in this presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material. This presentation contains financial measures and guidance which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with US generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. All GAAP to non-GAAP reconciliations are provided on our website.

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as non-GAAP adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

## Financial comparisons

References to results increasing, decreasing, or remaining flat are in comparison to the same period in the prior fiscal year. References to organic revenue growth exclude the impact of foreign currency and first quarter revenue in the current and prior year reported as "Other". Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to sequential revenue changes are made on an "as reported" basis. Unless stated otherwise, all references to share gains or losses are as of the most recently completed calendar quarter, on a revenue basis, and in comparison to the same period in the prior year.

# Table of contents

Q1 FY25  
Executive  
Summary

Portfolio  
Highlights

Financial  
Highlights

Guidance &  
Assumptions

Sustainability

Appendix



# Q1 FY25 Executive Summary

# Q1 FY25 Highlights

**Exceeding commitments, increasing outlook for the year, and restoring earnings power; 7<sup>th</sup> quarter in a row of mid-single digit revenue growth; Continued execution and innovation expected to generate strong returns to shareholders**



## Healthy underlying markets; driving operating rigor; new product innovation fueling diversified growth across many health tech growth markets

- Cardiovascular portfolio accelerated to high-single digit growth, and continued momentum in Neuroscience and Diabetes; innovation driving growth in AID, TAVR, PFA, Pain Stim, Brain Mod
- MSD US growth and HSD International growth, including mid-Teens EM growth
- Diversified growth from other businesses creating a solid foundation, and importantly generating profits and cash flow to fuel our growth businesses



## Investing in our future innovation pipeline to drive growth in the short-, medium-, and long-term

- At the front end of many new product cycles, in markets like Pulsed Field Ablation, Diabetes, TAVR, Surgical Robotics, Neuromodulation, and Renal Denervation



## Transformation taking hold; scale benefits; improved rigor; stronger performance

- Multiple franchises delivering, with growth acceleration in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes
- Driving scale across our manufacturing, technology, and commercial organizations, and continuing to make progress on ongoing portfolio management work
- Adj. gross margin up 30 bps Y/Y CC; operating margin up 60 bps Y/Y CC
- \$1.5B incremental net share repurchase since last earnings release; \$4B total over last two quarters



## Exceeded consensus organic revenue growth by 1% and EPS by \$0.03

- EPS beat vs consensus came from higher operating profit driven by revenue beat, as well as lower interest expense
- Versus consensus, benefit to EPS of lower share count fully offset by the impact of lower interest income



## Raising FY25 revenue and EPS guidance

- Encouraged by Q1 outperformance and positive momentum
- Organic revenue growth: 4.5% to 5% vs. prior 4% to 5%
  - Adjusted EPS: \$5.42 to \$5.50 vs. prior \$5.40 to \$5.50; implies growth of 4% to 6%



We executed, exceeded our commitments, and delivered another good quarter. Our underlying markets are healthy, we're driving operating rigor, and new product innovation is fueling diversified growth across key health tech markets. As we deliver innovation and execute on our transformation, we expect this to translate into strong returns for our shareholders."

**GEOFF MARTHA,  
CHAIRMAN & CEO**




**Medtronic**


# Q1 FY25 Financial summary



Revenue<sup>3</sup> by segment




Revenue<sup>3</sup> by geography



1) Full GAAP to non-GAAP reconciliation in Appendix  
 2) Operating cash flows less property, plant, and equipment additions.  
 3) Data has been intentionally rounded to the nearest million and, therefore, may not sum

# Key product approvals

Recent rapid cadence of meaningful innovative approvals; ~130 product approvals in last 12 months in key geographies<sup>1</sup>



Note: Relative positioning is not intended to signify relative timing  
 1) Includes US, EU, Japan and China. Does not include all indication or partner approvals, though select additional approvals are displayed



# Q1 FY25 Portfolio Highlights



# Cardiovascular

HSD growth driven by strong performance in PFA, Pacing, High Power, TAVR, Cardiac Surgery, and Coronary

## Cardiac Rhythm & Heart Failure (CRHF)


- Cardiac Pacing Therapies: LDD growth; low-20s WW Micra™ growth driven by continued momentum of Micra™ AV2 and VR2 in US & EU; low-30s WW SelectSure™ 3830 lead growth, only lead approved for all types of conduction system pacing in US
- Defibrillation Solutions: HSD growth driven by building TV Tachy momentum, strength in TYRX, and adoption of Aurora EV-ICD
- Cardiac Ablation Solutions: ~6.5% growth; sequential acceleration in WW growth driven by PulseSelect™; robust PFA growth partially offset by cryo declines; Affera Sphere9™ all-in-one wide-area focal catheter under FDA review

## Structural Heart & Aortic (SHA)

- Structural Heart: HSD WW growth excluding annualization of Harmony™ valve re-launch last year; strong positive response to Evolut™ FX+ limited market release with full market release now underway
- Aortic: MSD growth driven by strength in Thoracic stent graphs
- Cardiac Surgery: LDD growth on broad portfolio strength including ECLS; Pendenture™ LAA Clip US launch progressing as planned; next-gen Avalus Ultra™ aortic tissue valve launched in US

## Coronary and Peripheral Vascular (CPV)

- Coronary & Renal Denervation: HSD growth on Y/Y DES share gains driven by Onyx Frontier™ adoption; mid-teens growth in balloons and low-double digit growth in guide catheters
- Peripheral Vascular Health: HSD growth in DCBs driven by strength of IN.PACT™ 018 DCB; LDD growth in vascular embolization




**Micra™ AV2 and VR2**  
Transcatheter Pacing System



**Aurora EV-ICD™**  
System



**PulseSelect™ and Affera Sphere9™**  
Pulse Field Ablation (PFA) Catheters



**Evolut™ FX+**  
TAVR System



**Onyx Frontier™**  
DES

# Neuroscience

## MSD growth on continued strength in Spine and innovation-driven acceleration in Neuromodulation

### Cranial & Spinal Technologies (CST)


- Core Spine: HSD growth driven by AiBLE™ ecosystem pull-through, including Catalyft™ expandable interbody system and ModuLeX™ spinal system
- Biologics: HSD growth driven by the Grafton™ bone graft
- Neurosurgery: Growth on strength of AiBLE™ ecosystem including Mazor™ robotics, StealthStation™ navigation, O-arm™ imaging, and Midas Rex™ powered surgical instruments

### Specialty Therapies (ST)

- Neurovascular: MSD growth with continued strength in hemorrhagic stroke products
- Ear, Nose & Throat: LSD growth with decline in Standard Tubes offset by strong capital and localized drug delivery sinus implants
- Pelvic Health: LSD growth on continued adoption of the InterStim™ X system

### Neuromodulation (NM)

- Spinal Cord Stimulation: LDD growth driven by strong first quarter of US launch of Inceptiv™ closed-loop spinal cord stimulator
- Brain Modulation: Mid-teens growth driven by new implant growth of the Percept™ RC neurostimulator with BrainSense™ technology




**AiBLE™**  
Surgical Ecosystem



**ModuLeX™**  
Spinal System



**PROPEL™**  
Sinus Implant



**Inceptiv™**  
Rechargeable  
Closed-Loop SCS



**Percept™ RC DBS**  
with BrainSense™  
Technology



# Medical Surgical

LSD growth on difficult comps in Surgical; strength in Wound Management, Hernia & Emerging Markets; Continued progress on US Hugo™ IDE trials

## Surgical & Endoscopy (SE)

- Surgical LSD growth on difficult comparison from supply recovery in H1 FY24, as well as Korean market slowdown from physician strikes; HSD growth in EM, which is about a quarter of revenue mix; expect Surgical to return to more normalized growth in H2 FY25 as comparisons ease
- General Surgical Technologies: WW LSD growth driven by V-Loc™ and ProGrip™ Synthetic Mesh, which reduces the need for fixation and used in robotic cases given ease of use
- Advanced Surgical Technologies: WW LSD growth driven by Advanced Energy and LigaSure™ growth, partly offset by declines in Advanced Stapling given declines in US bariatric procedures
- Robotic Surgical Technologies: Reached targeted enrollment in Expand URO Trial; enrollment in Hugo™ US Hernia and GYN indication studies progressing well; installed base expansion OUS continues
- Endoscopy: Growth driven by strong market adoption of Endoflip™ 300 system and momentum in GI Genius™

## Acute Care & Monitoring (ACM)

- Blood Oxygen Management: Growth in Nellcor™ pulse oximetry driven by DD growth and strong adoption of RespArray™
- Airways: McGRATH™ MAC video laryngoscope HSD on strong adoption

**ProGrip™**  
Self-Fixating  
Mesh



**V-Loc™**  
Barbed Sutures

**Hugo™**  
RAS System




**McGRATH™**  
MAC Video  
Laryngoscope

**RespArray™**  
Patient Monitor



23% ●.....  
**ACM | \$452M**  
(1.5%) Y/Y Rep  
(0.1%) Y/Y Org



77%  
**SE | \$1,544M**  
(0.1%) Y/Y Rep  
1.3% Y/Y Org

# Diabetes

## Continued double-digit US and OUS growth on strong Automated Insulin Delivery system adoption

### United States

Continued adoption of the MiniMed780G system one year post launch driving strong performance in CGM and consumables return to growth

- Low-thirties CGM growth and increasing attachment rates demonstrating the success of our comprehensive AID system
- MiniMed™ 780G system saw +80% growth in new to pump therapy users; sustained growth in MDI users and competitive switches
- Secured FDA clearance of Simplera™ CGM; limited market release to begin pending submission and approval of updated InPen™ smart insulin pen app; Simplera Sync™ pending approval via a separate filing

### International


Continued double digit growth on increasing installed base and sensor attachment rates and ongoing roll-out of Simplera Sync™

- Initiated full market release of Simplera Sync™ sensor with continued positive feedback around ease of insertion and usage adding to the existing high satisfaction with the MiniMed™ 780G system
- Sequential Smart MDI install base growth with Simplera™ expanding to 19 EU countries
- Performance partially offset by market-wide reimbursement related headwinds in the UK and France which are expected to improve, and increasing competition

### Pipeline

Advancing next-gen pipeline to offer the largest portfolio of diabetes solutions

- Announced partnership with Abbott on an integrated CGM based on Abbott's most advanced CGM platform; exclusive for Medtronic across both automated insulin delivery and Smart MDI systems; expected to be accretive to Diabetes revenue and neutral to Diabetes gross margin
- Clinical trials advancing toward US FDA and CE mark labeling expansions for pregnancy, T2, pediatrics (2-6yo), ultra-rapid acting insulins for MiniMed™ 780G



1) Time In Range using recommended settings as shown in real-world evidence for MM780G system (n=5,762)

# Q1 FY25 Financial Highlights

# Q1 FY25 Adjusted income statement

| (\$ in millions) <sup>1</sup> | Q1 FY24 | Q1 FY25 | Y/Y                    |
|-------------------------------|---------|---------|------------------------|
| Adj. Revenue                  | \$7,702 | \$8,004 | 3.9%                   |
| <i>Organic revenue growth</i> |         |         | 5.3%                   |
| Gross Margin                  | 66.4%   | 65.9%   | (50 bps)<br>+30 bps CC |
| SG&A<br>% of Sales            | 33.4%   | 33.0%   | (40 bps)               |
| R&D<br>% of Sales             | 8.5%    | 8.4%    | (10 bps)               |
| Operating Margin              | 24.8%   | 24.4%   | (40 bps)<br>+60 bps CC |
| Net Income                    | \$1,596 | \$1,592 | (0.3%)                 |
| Diluted EPS                   | \$1.20  | \$1.23  | 2.5%<br>+7.5% CC       |

# Guidance & Assumptions

# Guidance and assumptions

| FY25 REVENUE                        | FY24 base                           | Organic revenue growth guidance | FX <sup>1</sup>      | Inorganic | Other <sup>2</sup> | Implied adjusted revenue range <sup>2</sup> |
|-------------------------------------|-------------------------------------|---------------------------------|----------------------|-----------|--------------------|---|
| Q4 Earnings Call<br>May 23, 2024    | FY24 Reported<br>\$32,364M          | <b>4.0% to 5.0%</b>             | (\$375M) to (\$275M) | \$0       | ~\$80M             | ~\$33.1B to \$33.6B                         |
|                                     | Less Other <sup>1</sup><br>(\$221M) |                                 |                      |           |                    |   |
| Q1 Earnings Call<br>August 20, 2024 | FY24 base<br><b>\$32,143M</b>       | <b>4.5% to 5.0%</b>             | (\$210M) to (\$110M) | \$0       | ~\$100M            | ~\$33.5B to \$33.7B                         |

| FY25 EPS                            | FY24 base | Implied constant currency growth | FX <sup>1</sup> | FY25 EPS guidance       |
|-------------------------------------|-----------|----------------------------------|-----------------|-------------------------|
| Q4 Earnings Call<br>May 23, 2024    |           | +9% to +11%                      | ~(5%)           | \$5.40 to \$5.50        |
|                                     | \$5.20    |                                  |                 |                         |
| Q1 Earnings Call<br>August 20, 2024 |           | +9% to +11%                      | ~(5%)           | <b>\$5.42 to \$5.50</b> |

Note: EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year

- 1) While FX rates are fluid, assumptions above are based on rates as of the beginning of August 2024
- 2) Includes Mozarc Medical Manufacturing & Servicing Agreements, Cardinal Health Manufacturing Agreements, Ventilation Service Solutions; does not include impact from Italian MedTech Payback





# Sustainability

# Leading in engagement, citizenship & innovation



Ethisphere  
One of the 2024 World's Most Ethical Companies®



Just Capital  
One of America's Most JUST Companies in 2024



Great Place to Work® certified awarded to Medtronic in Australia, Greater China, Spain, and 20 other countries



Dow Jones Sustainability Index  
DJSI World Index for 2 consecutive years  
DJSI North American Index for 15 consecutive years



U.S. Chamber of Commerce Foundation  
US Chamber of Commerce Foundation Best Corporate Citizens Awards  
Named Best Corporate Steward - Large Business



Top Employers Institute certified  
Awarded to Medtronic in the U.K., Egypt, South Africa, and 6 other countries



2023 Disability:IN and the American Association of People with Disabilities Disability Equality Index® Best Places to Work™ – 100% Score 6<sup>th</sup> consecutive year with top score



2023 Hispanic Association on Corporate Responsibility  
5-star awards across all 4 pillars – Employment, Philanthropy, Procurement, & Governance – 2<sup>nd</sup> consecutive year



IR Magazine  
2024 Best Investor Targeting strategy; Finalist for Best IR in Healthcare

# Near and long-term sustainability objectives

## Robust governance structures and processes underpin our sustainability strategy



Carbon neutral in Operations (scope 1 and 2)



Net-zero emissions

| Sustainability targets and progress |   | Baseline | End date | FY23 status                    |
|-------------------------------------|---|----------|----------|--------------------------------|
| Climate stewardship                 | Reduce greenhouse gas emissions intensity by 50%  | FY20     | FY25     | <b>35%</b>                     |
|                                     | Reduce energy intensity by 20%  | FY20     | FY25     | <b>6%</b>                      |
|                                     | Source 50% of energy from renewable and alternative sources   | FY20     | FY25     | <b>31%<sup>1</sup></b>         |
|                                     | Reduce water usage intensity by 15%   | FY20     | FY25     | <b>9%</b>                      |
|                                     | Reduce waste intensity by 15%   | FY20     | FY25     | <b>17%</b>                     |
|                                     | Become carbon neutral in our operations (scope 1 and 2)   | N/A      | FY30     | <b>On track</b>                |
|                                     | Reach net-zero emissions  | N/A      | FY45     | <b>On track</b>                |
| Product stewardship                 | Reduce packaging waste by 25% for four <sup>2</sup> targeted high-volume product families <sup>3</sup>  | FY21     | FY25     | <b>7%</b>                      |
|                                     | Minimize impact of instructions for use (IFU) through a 35% paper reduction   | FY21     | FY27     | <b>1%</b>                      |
|                                     | Publish partial life cycle assessments (LCA) for 100% of products and full LCAs for 50% of products   | N/A      | FY30     | <b>New in FY23</b>             |
|                                     | Convert 50% of eligible product codes to electronic IFUs within applicable regions  | N/A      | FY30     | <b>New in FY23</b>             |
|                                     | Integrate circularity and eco-design criteria into the New Product Development process  | N/A      | FY30     | <b>New in FY23</b>             |
|                                     | Achieve one of the following for 95% of eligible plastic packaging: is industrially recyclable, contains postindustrial recycled content, demonstrates optimized design | N/A      | FY30     | <b>New in FY23</b>             |
| Access and Innovation               | Reduce packaging for 20 additional high-volume products for a total of 50% reduction  | N/A      | FY30     | <b>New in FY23</b>             |
|                                     | Flow 20% of revenue from products released in the prior 36 months (vitality index)  | N/A      | FY25     | <b>16%</b>                     |
| Product quality                     | Serve 79 million patients annually through strategies that increase healthcare access <sup>4</sup>  | N/A      | FY25     | <b>78 million+<sup>6</sup></b> |
|                                     | Reduce aggregate product complaint rate by 10% for identified product families <sup>5</sup>   | FY20     | FY25     | <b>39%</b>                     |
| ID&E                                | Reach 45% representation of women in manager-and-above roles globally through focus on effective practices  | N/A      | FY26     | <b>43%</b>                     |
|                                     | Reach 30% representation of ethnically diverse groups in manager-and-above roles in the US through focus on effective practices   | N/A      | FY26     | <b>28%</b>                     |
|                                     | Increase spend with US diverse-owned suppliers by 5% Y/Y through FY26 through focus on effective practices  | FY22     | FY23     | <b>37%</b>                     |

1) Annual progress is cumulative and represented as the growth in sourcing over the FY20 baseline year. Value includes purchases renewable electricity credits.

2) Four product families include: Tri-staple, Polysorb, Absorbatack, Spinal Implants


3) High-volume product families identified based on weight, material selection, and sourcing

4) Target was adjusted in FY23 after announcement of plans to divest the PMRI businesses

5) For more information see page 17 of the FY23 Sustainability Report found on the Medtronic [Investor Relations website](#)

6) Based on FY24 10-K

Next update will be available in the FY24 report later this fall



# Appendix

# Q1 FY25 Revenue by portfolio and geography

|                                | Worldwide                  |                  |              | United States              |                  |              | International              |                  |              |
|--------------------------------|----------------------------|------------------|--------------|----------------------------|------------------|--------------|----------------------------|------------------|--------------|
|                                | Revenue (\$M) <sup>1</sup> | As reported Y/Y% | Organic Y/Y% | Revenue (\$M) <sup>1</sup> | As reported Y/Y% | Organic Y/Y% | Revenue (\$M) <sup>1</sup> | As reported Y/Y% | Organic Y/Y% |
| <b>Cardiovascular</b>          | <b>3,007</b>               | <b>5.5%</b>      | <b>6.9%</b>  | <b>1,403</b>               | <b>3.9%</b>      | <b>3.9%</b>  | <b>1,604</b>               | <b>6.9%</b>      | <b>9.5%</b>  |
| Cardiac Rhythm & Heart Failure | 1,535                      | 6.2%             | 7.5%         |                            |                  |              |                            |                  |              |
| Structural Heart & Aortic      | 856                        | 5.1%             | 6.6%         |                            |                  |              |                            |                  |              |
| Coronary & Peripheral Vascular | 616                        | 4.5%             | 5.8%         |                            |                  |              |                            |                  |              |
| <b>Neuroscience</b>            | <b>2,317</b>               | <b>4.4%</b>      | <b>5.3%</b>  | <b>1,565</b>               | <b>4.5%</b>      | <b>4.5%</b>  | <b>752</b>                 | <b>4.3%</b>      | <b>6.8%</b>  |
| Cranial & Spinal Technologies  | 1,147                      | 4.0%             | 4.8%         |                            |                  |              |                            |                  |              |
| Specialty Therapies            | 713                        | 2.5%             | 3.4%         |                            |                  |              |                            |                  |              |
| Neuromodulation                | 457                        | 8.9%             | 9.6%         |                            |                  |              |                            |                  |              |
| <b>Medical Surgical</b>        | <b>1,996</b>               | <b>-0.4%</b>     | <b>1.0%</b>  | <b>881</b>                 | <b>1.6%</b>      | <b>1.6%</b>  | <b>1,115</b>               | <b>-2.0%</b>     | <b>0.5%</b>  |
| Surgical & Endoscopy           | 1,544                      | -0.1%            | 1.3%         |                            |                  |              |                            |                  |              |
| Acute Care & Monitoring        | 452                        | -1.5%            | -0.1%        |                            |                  |              |                            |                  |              |
| <b>Diabetes</b>                | <b>647</b>                 | <b>11.8%</b>     | <b>12.6%</b> | <b>215</b>                 | <b>14.3%</b>     | <b>14.3%</b> | <b>432</b>                 | <b>10.7%</b>     | <b>11.7%</b> |
| <b>Other</b>                   | <b>-52</b>                 | <b>-203.7%</b>   |              | <b>18</b>                  | <b>-15.6%</b>    |              | <b>-70</b>                 | <b>-347.5%</b>   |              |
| <b>Total Medtronic</b>         | <b>7,915</b>               | <b>2.8%</b>      | <b>5.3%</b>  | <b>4,082</b>               | <b>4.0%</b>      | <b>4.1%</b>  | <b>3,832</b>               | <b>1.5%</b>      | <b>6.5%</b>  |

# Q1 FY25 GAAP to non-GAAP reconciliations

|   | Q1 FY25 GAAP | Amortization | Restructuring | Acquisition and Divestiture-Related Items | Certain Litigation | (Gain) / Loss on Minority Investments | Medical Device Regulations | Other       | Certain Tax Adjustments | Q1 FY25 Non-GAAP | Q1 FY24 Non-GAAP | Y/Y Growth / Change |
|---|--------------|--------------|---------------|---|--------------------|---------------------------------------|----------------------------|-------------|-------------------------|------------------|------------------|---------------------|
| <b>Net Sales</b>                            | <b>7,915</b> | -            | -             | -   | -                  | -                                     | -                          | <b>90</b>   | -                       | <b>8,004</b>     | <b>7,702</b>     | <b>3.9%</b>         |
| Cost of Products Sold                       | 2,761        | -            | (9)           | (10)                                      | -                  | -                                     | (11)                       | -           | -                       | 2,730            | 2,586            | 5.6%                |
| <b>Gross Margin</b>                         | <b>65.1%</b> | -            | <b>0.1%</b>   | <b>0.1%</b>                               | -                  | -                                     | <b>0.1%</b>                | <b>0.6%</b> | -                       | <b>65.9%</b>     | <b>66.4%</b>     | <b>50 bps</b>       |
| SG&A  | 2,655        | -            | (5)           | (7)                                       | -                  | -                                     | -                          | -           | -                       | 2,642            | 2,575            | 2.6%                |
| % of Sales                                  | 33.5%        | -            | (0.2%)        | (0.3%)                                    | -                  | -                                     | -                          | -           | -                       | 33.0%            | 33.4%            | (40 bps)            |
| R&D   | 676          | -            | -             | -   | -                  | -                                     | (3)                        | -           | -                       | 673              | 658              | 2.3%                |
| % of Sales                                  | 8.5%         | -            | -             | 0.1%                                      | -                  | -                                     | -                          | -           | -                       | 8.4%             | 8.5%             | (10 bps)            |
| Other Operating Expense (Income), Net       | 1            | -            | -             | 6   | -                  | -                                     | -                          | -           | -                       | 7                | (26)             | (126.9%)            |
| % of Sales                                  | -            | -            | -             | 0.1%                                      | -                  | -                                     | -                          | -           | -                       | 0.1%             | (0.3%)           | (40 bps)            |
| Amortization of Intangible Assets           | 414          | (414)        | -             | -   | -                  | -                                     | -                          | -           | -                       | -                | -                | -                   |
| Restructuring Charges, Net                  | 47           | -            | (47)          | -   | -                  | -                                     | -                          | -           | -                       | -                | -                | -                   |
| Certain Litigation Charges                  | 81           | -            | -             | -   | (81)               | -                                     | -                          | -           | -                       | -                | -                | -                   |
| <b>Operating Profit</b>                     | <b>1,278</b> | <b>414</b>   | <b>62</b>     | <b>12</b>                                 | <b>81</b>          | -                                     | <b>14</b>                  | <b>90</b>   | -                       | <b>1,953</b>     | <b>1,909</b>     | <b>2.3%</b>         |
| <b>Operating Margin</b>                     | <b>16.1%</b> | <b>5.1%</b>  | <b>0.8%</b>   | <b>0.1%</b>                               | <b>1.0%</b>        | -                                     | <b>0.2%</b>                | <b>1.1%</b> | -                       | <b>24.4%</b>     | <b>24.8%</b>     | <b>(40 bps)</b>     |
| Other Non-Operating Income, Net             | (157)        | -            | -             | -   | -                  | 17                                    | -                          | -           | -                       | (140)            | (141)            | (0.7%)              |
| <b>Net Income Attributable to MDT (\$M)</b> | <b>1,042</b> | <b>340</b>   | <b>51</b>     | <b>11</b>                                 | <b>68</b>          | <b>(17)</b>                           | <b>11</b>                  | <b>70</b>   | <b>17</b>               | <b>1,592</b>     | <b>1,596</b>     | <b>(0.3%)</b>       |
| <b>Diluted EPS (\$)<sup>(1)</sup></b>       | <b>0.80</b>  | <b>0.26</b>  | <b>0.04</b>   | <b>0.01</b>                               | <b>0.05</b>        | <b>(0.01)</b>                         | <b>0.01</b>                | <b>0.05</b> | <b>0.01</b>             | <b>1.23</b>      | <b>1.20</b>      | <b>2.5%</b>         |

# Medtronic business structure



## Cardiovascular

[Learn more](#)

### Cardiac Rhythm & Heart Failure

- Cardiac Rhythm Management
- Cardiac Ablation Solutions

### Structural Heart & Aortic

- Structural Heart & Aortic
- Cardiac Surgery

### Coronary & Peripheral Vascular

- Coronary & Renal Denervation
- Peripheral Vascular Health



## Neuroscience


[Learn more](#)

### Cranial & Spinal Technologies

#### Specialty Therapies

- Neurovascular
- Ears, Nose & Throat (ENT)
- Pelvic Health

#### Neuromodulation




## Medical Surgical

[Learn more](#)

### Surgical & Endoscopy

- Surgical
- Endoscopy


### Acute Care & Monitoring



## Diabetes

[Learn more](#)

Therapies and services for insulin-dependent people who have Type 1 and Type 2



## Other

- Cardinal Health Manufacturing Agreements
- Mozarc Medical Manufacturing & Servicing Agreements
- Ventilation Service Solutions

# Abbreviations & acronyms

| Growth |                                     | Business specific |  | Business specific |  | Other |                                  |
|--------|-------------------------------------|-------------------|--|-------------------|--|-------|----------------------------------|
| CC     | Constant Currency                   | AID               | Automated Insulin Delivery                           | ICD               | Implantable Cardioverter Defibrillator | ACC   | American College of Cardiology   |
| WAMGR  | Weighted Average Market Growth Rate | CAS               | Cardiac Ablation Solutions                           | LAA               | Left Atrial Appendage                  | EM    | Emerging Markets                 |
|        |                                     | CGM               | Continuous Glucose Monitoring                        | MDI               | Multiple Daily Injections              | FIH   | First-In-Human                   |
|        |                                     | CRM               | Cardiac Rhythm Management                            | PFA               | Pulse Field Ablation                   | HCP   | Health Care Provider             |
|        |                                     | DBS               | Deep Brain Stimulation                               | RAS               | Robot-Assisted Surgery                 | IDE   | Investigational Device Exemption |
|        |                                     | DCB               | Drug Coated Balloon                                  | RDN               | Renal Denervation                      | ID&E  | Inclusion, Diversity and Equity  |
|        |                                     | DES               | Drug Eluting Stent                                   | SCS               | Spinal Cord Stimulation                | LMR   | Limited Market Release           |
|        |                                     | DTM               | Differential Target Multiplexed Waveform             | TAR               | Time Above Range                       | NEJM  | New England Journal of Medicine  |
|        |                                     | ECLS              | Extracorporeal life support                          | TAA               | Thoracic Aortic Aneurysm               | NMPA  | National Medical Products Admin. |
|        |                                     | ENT               | Ear, Nose, & Throat                                  | TAVR              | Transcatheter Aortic Valve Replacement | OU    | Operating Unit                   |
|        |                                     | EV-ICD            | Extravascular Implantable Cardioverter Defibrillator | TIR               | Time In Range                          | VBP   | Volume-Based Procurement         |
|        |                                     | GI                | Gastrointestinal                                     | TV Tachy          | Transvenous tachycardia                | WE    | Western Europe                   |
|        |                                     | GYN               | Gynecology   | URO               | Urology                                | WW    | World Wide                       |



# Medtronic

Engineering the extraordinary

## Investor Relations contact information



**Ryan Weispfenning**

Vice President,  
Head of Investor Relations



**Brad Welnick**

Vice President,  
Investor Relations & FP&A

[investor.relations@medtronic.com](mailto:investor.relations@medtronic.com)



Medtronic